Marion E. Scoggins - Concepedia

Author

Marion E. Scoggins

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

M. E. Scoggins, M. Scoggins, M.E. Scoggins, Marion E Scoggins, Marion E. Scoggins, Marion Elizabeth Scoggins, Marion Scoggins

Publications

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Baylor College of Medicine Dana-Farber Brigham Cancer Center Brigham and Women's Hospital

About

Marion E. Scoggins is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, breast cancer, and radiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	256
2	Health Sciences	3	3	61
3	Engineering	2	2	28
4	Anatomy	1	1	11
5	Biomedical Engineering	1	1	15

Marion E. Scoggins

Publications

796

Citations

H-Index

Page 1

	Year	Citations
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline <i>BRCA</i> Pathogenic Variant Jennifer K. Litton, Marion E. Scoggins, Kenneth R. Hess, Journal of Clinical Oncology	2019	187
Microcalcifications in 1657 Patients with Pure Ductal Carcinoma in Situ of the Breast: Correlation with Clinical, Histopathologic, Biologic Features, and Local Recurrence Gaiane M. Rauch, Brian P. Hobbs, Henry M. Kuerer, Annals of Surgical Oncology Tumoral PathologyBreast OncologyBiologic FeaturesCancer DetectionMedicine	2015	56
A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity Jennifer K. Litton, Marion E. Scoggins, David L. Ramírez, npj Breast Cancer	2017	56
Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status Gaiane M. Rauch, Henry M. Kuerer, Marion E. Scoggins, Breast Cancer Research and Treatment Breast OncologyMedicineGynecologyBreast ImagingBreast Cancer	2013	51
Correlation Between Sonographic Findings and Clinicopathologic and Biologic Features of Pure Ductal Carcinoma In Situ in 691 Patients Marion E. Scoggins, Patricia S. Fox, Henry M. Kuerer, American Journal of Roentgenology	2015	44
Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI Zijian Zhou, Beatriz E. Adrada, Rosalind P. Candelaria, Scientific Reports	2023	40
Triple-Negative Breast Cancer: Histopathologic Features, Genomics, and Treatment Beatriz E. Adrada, Tanya W. Moseley, Megha Kapoor, Radiographics	2023	36
American College of Radiology–Compliant Short Protocol Breast MRI for High-Risk Breast Cancer Screening: A Prospective Feasibility Study Başak E. Doğan, Marion E. Scoggins, Jong Bum Son, American Journal of Roentgenology	2017	33
Neoadjuvant talazoparib (TALA) for operable breast cancer patients with a BRCA mutation (BRCA+). Jennifer K. Litton, Marion E. Scoggins, Kenneth R. Hess, Journal of Clinical Oncology Surgical OncologyNeoadjuvant TalazoparibBrca MutationWindow TrialBreast Oncology	2018	33
Prospective Registry Trial Assessing the Use of Magnetic Seeds to Locate Clipped Nodes After Neoadjuvant Chemotherapy for Breast Cancer Patients Janine M. Simons, Marion E. Scoggins, Henry M. Kuerer, Annals of Surgical Oncology Magnetic SeedsBreast OncologyNeoadjuvant ChemotherapyBreast Cancer PatientsMedicine	2021	29

Page 1